149690-05-1

Sacubitril is an angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases.

(Z)2S,4R-Sacubitril is an impurity of Sacubitril, a compound used in combination with valsartan for treating patients with heart failure.

Sacubitril-(2S,4S)-Isomer ((2S,4S)-Sacubitril) is the isomer of Sacubitril which is a neprilysin inhibitor.

(2S,4S)-Sacubitril (Sacubitril Impurity C) is a stereoisomer derived from Sacubitril which is a potent NEP inhibitor.

Sacubitril hemicalcium salt (AHU377 calcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696. Sacubitril hemicalcium salt is a prodrug of LBQ657, which is an inhibitor of the zinc metallopeptidase neprilysin. Neprilysin degrades a variety of vasoactive peptides such as atrial and brain natriuretic peptide, bradykinin, adrenomedullin, and endothelin-1. Inhibition of neprilysin leads to an increased level of these peptides and, thus, antihypertensive effects. Formulations containing AHU377 in combination with the angiotensin II receptor antagonist valsartan are used to treat hypertension and heart failure.

AHU-377-d4 is a deuterated compound of AHU-377.

2R,4S-Sacubitril (Sacubitril Enantiomer) is the impurity of Sacubitril which is a neprilysin inhibitor.

Sacubitril Enantiomer (ahu377 isomer 2) is the enantiomer of Sacubitril which is a neprilysin inhibitor.

Sacubitril-d4 calcium salt is a deuterated compound of Sacubitril calcium salt.

Sacubitril Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for the treatment of hypertension and heart failure.

Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM and is a component of the heart failure medicine LCZ696.